RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hubei Minkang Pharmaceutical Stock

Hubei Minkang Pharmaceutical ROA 2024

Hubei Minkang Pharmaceutical ROA

0

Ticker

HBMK

ISIN

US44352W1018

In 2024, Hubei Minkang Pharmaceutical's return on assets (ROA) was 0, a 0% increase from the 0 ROA in the previous year.

Hubei Minkang Pharmaceutical Aktienanalyse

What does Hubei Minkang Pharmaceutical do?

Hubei Minkang Pharmaceutical Ltd is a Chinese pharmaceutical company that was founded in 1988. Since its establishment, the company has specialized in the development, production, and sale of medicines, particularly traditional Chinese medicines. The company is based in Xianning City, Hubei Province, and employs over 1,000 staff, including over 400 technicians and researchers. It is a leading manufacturer of medicines in China and has a good reputation in the national and international markets. Hubei Minkang Pharmaceutical has a wide business model that specializes in the development and marketing of medicines in various areas. These include: - Traditional Chinese Medicine: Traditional Chinese Medicine (TCM) is one of the company's specialties. TCM is a holistic approach that focuses on the body's natural healing powers. It involves the use of plants, minerals, and animal products to treat diseases and ailments. The company develops and produces a variety of TCM products that are highly valued by Chinese society. - State-of-the-Art Medicines: The company has also invested in modern medicines in recent years and has a specialized research and development department to develop these products. The portfolio also includes impressive developments in cancer therapy and treatment options for cardiovascular diseases. - Veterinary Medicine: Hubei Minkang Pharmaceutical Ltd also produces a wide range of products used in veterinary medicine. This includes remedies for parasites, antibiotics, and vitamins. - Research and Development: The company has established itself as an innovation driver through investment in the research and development of medicines. Hubei Minkang Pharmaceutical Ltd has been awarded with high-quality assurance and boasts a modern production facility that is standardized at the international level. The company has also received certifications from global institutions such as Good Manufacturing Practice (GMP). This ensures that all products are of the highest quality, safety, and efficacy. The company is committed to achieving its self-set corporate goals in a sustainable manner, thus creating a sense of shared responsibility towards the environment and society. Overall, Hubei Minkang Pharmaceutical Ltd is a company that focuses on the development, production, and sale of medicines, particularly traditional Chinese medicine. It has established itself as a successful player in the national and international markets through its specialized divisions and modern manufacturing processes. Hubei Minkang Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Hubei Minkang Pharmaceutical's Return on Assets (ROA)

Hubei Minkang Pharmaceutical's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Hubei Minkang Pharmaceutical's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Hubei Minkang Pharmaceutical's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Hubei Minkang Pharmaceutical’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Hubei Minkang Pharmaceutical stock

What is the Return on Assets (ROA) of Hubei Minkang Pharmaceutical this year?

The Return on Assets (ROA) of Hubei Minkang Pharmaceutical is 0 undefined this year.

What was the ROA of Hubei Minkang Pharmaceutical compared to the previous year?

The ROA of Hubei Minkang Pharmaceutical has increased by 0% compared to the previous year.

What consequences do high ROA have for investors of Hubei Minkang Pharmaceutical?

A high ROA is advantageous for investors of Hubei Minkang Pharmaceutical, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Hubei Minkang Pharmaceutical?

A low ROA can be unfavorable for investors of Hubei Minkang Pharmaceutical as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Hubei Minkang Pharmaceutical affect the company?

An increase in ROA of Hubei Minkang Pharmaceutical can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Hubei Minkang Pharmaceutical impact the company?

A reduction in the ROA of Hubei Minkang Pharmaceutical can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Hubei Minkang Pharmaceutical?

Some factors that can influence the ROA of Hubei Minkang Pharmaceutical include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Hubei Minkang Pharmaceutical important for investors?

The ROA of Hubei Minkang Pharmaceutical is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Hubei Minkang Pharmaceutical take to improve ROA?

To improve ROA, Hubei Minkang Pharmaceutical can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Hubei Minkang Pharmaceutical pay?

Over the past 12 months, Hubei Minkang Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hubei Minkang Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Hubei Minkang Pharmaceutical?

The current dividend yield of Hubei Minkang Pharmaceutical is .

When does Hubei Minkang Pharmaceutical pay dividends?

Hubei Minkang Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hubei Minkang Pharmaceutical?

Hubei Minkang Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Hubei Minkang Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hubei Minkang Pharmaceutical located?

Hubei Minkang Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hubei Minkang Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hubei Minkang Pharmaceutical from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Hubei Minkang Pharmaceutical pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Hubei Minkang Pharmaceutical in the year 2023?

In the year 2023, Hubei Minkang Pharmaceutical distributed 0 USD as dividends.

In which currency does Hubei Minkang Pharmaceutical pay out the dividend?

The dividends of Hubei Minkang Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hubei Minkang Pharmaceutical

Our stock analysis for Hubei Minkang Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hubei Minkang Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.